Literature DB >> 28669216

Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.

Alexandra Sophie Moss1,2, Gerasimos Dimitropoulos1,2, Derek L Connolly2, Gregory Y H Lip1,3.   

Abstract

INTRODUCTION: Atrial fibrillation (AF) and diabetes mellitus (DM) are common worldwide and their incidence is increasing, representing a significant public health and economic burden as well as an increase in individual increased morbidity and mortality risk profiles. Both conditions are closely related, as patients with DM are at increased risk of incident AF, and AF patients with DM are at higher risk of cardiovascular events compared to non-AF patients. Areas covered: This review article aims to provide an overview of the current evidence linking DM and AF, as well as the impact of obesity, weight loss and stroke on these coexisting conditions. Second, the effects of new oral anti hyperglycaemic medications on cardiovascular risk will be considered. Expert opinion: In conclusion, coexisting AF and DM represent a high risk population of patients requiring aggressive risk factor identification and treatment optimisation. The multifactorial interplay between these conditions requires individual assessment of patient risk profiles with the aim of minimising the impact of each modifiable risk factor.

Entities:  

Keywords:  Anticoagulation; atrial fibrillation; diabetes; empagliflozin; obesity; stroke

Mesh:

Substances:

Year:  2017        PMID: 28669216     DOI: 10.1080/14656566.2017.1350647

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

2.  The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.

Authors:  Ann Wan-Chin Ling; Cze-Ci Chan; Shao-Wei Chen; Yi-Wei Kao; Chien-Ying Huang; Yi-Hsin Chan; Pao-Hsien Chu
Journal:  Cardiovasc Diabetol       Date:  2020-11-06       Impact factor: 9.951

3.  SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.

Authors:  Wen-Jie Li; Xing-Qing Chen; Ling-Ling Xu; Yuan-Qing Li; Bi-Hui Luo
Journal:  Cardiovasc Diabetol       Date:  2020-08-26       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.